Clinical trials: Alzheimer Blood Biomarkers
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NPC1-AD (NCT07236190)
- Testing
- natural product combination-1 (NPC1)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Dementia With Lewy Bodies, Alzheimer Disease
DIagnostic Biomarkers and Symptoms in Patients With Alzheimer's Disease and Lewy bodY Dementia
This a study to improve diagnosis of dementia with Lewy bodies with RT-QuIC in different biospecimens.
- Conditions
- Dementia With Lewy Bodies, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- DISPLAY (NCT05768425)
- Testing
- Real-time quaking-induced conversion (RT-QuIC), Cognitive test, Motor examination
- Where
- Denmark
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Danish Dementia Research Centre
Dementia of Alzheimer Type, Alzheimer Disease
Prevalence of Alzheimer's Disease Pathology in the Community
The goal of this observational study is to (I) study the proportion of people with Alzheimer's disease pathology in a large Norwegian population-based cohort of people aged 70 years or older and to (II) study longitudinal changes…
- Conditions
- Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment, Pathology
- Trial name
- HUNT4AD (NCT06719453)
- Volunteers
- 9,663 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Alzheimer's Plasma Extension
The goal of this observational study is to learn how Alzheimer's disease-related blood biomarkers, brain amyloid, and memory and thinking abilities change over time.
- Trial name
- APEX (NCT06416072)
- Testing
- NAV4694
- Where
- 56 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Preclinical Alzheimer
β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline
The overall (cross-sectional) objective of this study is to detect and describe the profile of AD-related blood biomarkers in a population with SCD (including individuals with MCI) with the ultimate goal of investigating their…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer, Mild Cognitive Impairment
- Trial name
- β-AARC (NCT04935372)
- Testing
- Observational
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Alzheimer's Disease
A Pilot Study of Inflammatory Markers in Alzheimer's Disease
The purpose of this study is to examine the cerebrospinal fluid (CSF) of patients with Alzheimer's disease for biomarkers of inflammation and their response to the antibiotics doxycycline and rifampin.
- Trial name
- NCT00715858
- Testing
- doxycycline, rifampin
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- McMaster University
Alzheimer Disease, Parkinson Disease
The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)
The complex pathological cascades leading to both Alzheimer's disease (AD) and Parkinson's disease (PD) involve, at various points, inflammation.
- Conditions
- Alzheimer Disease, Parkinson Disease, Inflammation
- Trial name
- NCT03702816
- Testing
- GE180 PET Scan
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Aaron Ritter, MD
Alzheimer Disease
Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers
This is an observational study that will collect blood from a finger prick (Capitainer SEP10 single channel device) and assess the accuracy of pTau-217 testing in comparison to previously collected venous blood samples from the…
- Trial name
- eDROP-AD (NCT07187921)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Banner Health
Alzheimer Blood Biomarkers, Alzheimer's Disease (AD)
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care.
- Trial name
- BRIDGE-AD2 (NCT07680335)
- Testing
- Plasma p-tau217 and neurofilament light chain results
- Where
- 8 sites in Netherlands
- Volunteers
- 550 people
- Sponsor
- Alzheimercentrum Amsterdam
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
Predicting Pre-dementia
The goal of this observational study is to learn how well a multimodal "Progression and Risk" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
- Trial name
- NCT07516119
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prevention Research Consortium Corp.
Alzheimer Disease, Cognitive Impairment
The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers
The goal of this observational study is to determine whether the early adoption of blood-based biomarkers for Alzheimer's disease is associated with an impact on etiological diagnosis, patient's management, emotional impact…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Dementia, Neurodegenerative Diseases
- Trial name
- PLASMAR (NCT06246019)
- Testing
- Early adoption of blood-based biomarkers for Alzheimer's disease
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Hospital del Mar Research Institute (IMIM)
Alzheimer Disease
Study on Novel Peripheral Blood Diagnostic Biomarkers for MCI Due to Alzheimer's Disease
The prevalence of Mild Cognitive Impairment (MCI) is about 15%-17%. 10%-15% of MCI progresses to Alzheimer's disease (AD) every year. The annual incidence of MCI in the normal elderly is about 1%.
- Trial name
- Precision1000 (NCT04509271)
- Testing
- MicRNAs battery kits
- Where
- China
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
Digital Technology Combined With Blood Marker Screening and Diagnosis for Community Populations Based on Classification Theory: an Integrated Study
Our research hypothesis is as follows: A step - by - step screening strategy based on screening technologies can resolve the issue of insufficient efficiency in the traditional scale - based screening model.
- Trial name
- NCT07286812
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- First Hospital of China Medical University
Alzheimer's Disease
A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
The aim of the study is to determine if regional cerebral blood flow, measured by dynamic arterial spin labeling (dASL), can be a biomarker for stage of Alzheimer's disease.
- Trial name
- NCT00757939
- Testing
- MRI, FDG-PET
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Alzheimer Biomarkers on CSF of Elderly Patients Undergoing Surgery
Dementia is a syndrome characterized by cognitive and behavioral impairment in older adults, which usually manifests as memory loss, communication difficulties or changes in mood.
- Trial name
- NCT03977025
- Testing
- Lumbar punction
- Where
- Chile
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Chile
Mild Cognitive Impairment, Alzheimer Disease
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers
This study evaluates a diagnostic screening solution for Alzheimer's disease (AD) using digital cognitive assessments and blood-based biomarkers.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- NCT07041450
- Testing
- Digital MoCA, XpressO, MoCA
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- MoCA Clinic and Institute
Alzheimer's Disease
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
- Trial name
- NCT06043700
- Testing
- No Intervention
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eisai Limited